Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of advanced malignancy:
* Treatment Group A (TGA): Part 1 and Part 2: Any advanced solid tumor or lymphoma; Part 3: Histologically confirmed disease in specific solid tumors and lymphomas
* Treatment Group B (TGB): Acute Leukemia (Part 3 - acute myeloid leukemia \[AML\] only), myelodysplastic syndrome (MDS), myelodysplastic /myeloproliferative neoplasms (MDS/MPN) and myelofibrosis (MF)
* Treatment Group C (TGC): Multiple myeloma
Progressed following at least 1 line of prior therapy and there is no further approved therapy available that has been demonstrated to prolong survival (including subjects who are intolerant to the approved therapy)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 in Parts 1 and 2 dose escalation and titration, and 0, 1, 2 in Part 3 dose expansion
You may not be if
Inadequate hematopoietic, liver, endocrine or renal function
Receipt of anticancer medications or investigational drugs within the following interval before the first administration of study drug:
* \< 6 weeks for mitomycin-C or nitrosoureas
* \< 5 half-lives or 14 days, whichever is longer, for any investigational agent (for any indication)
* \< 28 days for any antibodies or biological therapies
* \< 5 half-lives for all other anticancer medications, or sponsor approval
Prior radiotherapy within 2 weeks prior to first dose of study drug
Untreated brain or central nervous system (CNS) metastases
Type 1 diabetes or uncontrolled Type 2 diabetes
Any sign of clinically significant bleeding
Clareo Health | An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
